Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lilja B Solnes

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2018
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to ArmsRoberto A Salas Fragomeni, Tali Amir, Sara Sheikhbahaei, et al.
BJU International|September 23, 2024
The use of <sup>99m</sup>Tc-tetrofosmin in the characterisation of indeterminate renal masses: a pilot studyErgi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerAndrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2025
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [<sup>177</sup>Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate CancerLoïc Djaileb, Andrea Farolfi, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 11, 2025
[<sup>68</sup>Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based ChemotherapyStephan Beintner-Skawran, Andrei Gafita, Theo Lorenzini, et al.
Journal of the American College of Radiology : JACR|March 21, 2026
ACR Appropriateness Criteria® Penetrating Trauma-Abdomen and Pelvis: Update 2026, Daniel N Costa, Michael Bass, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
PSMA PET/CT-Derived Indicators and Outcomes After [<sup>177</sup>Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access ProgramKoichiro Kimura, Vishnu Murthy, Andrew F Voter, et al.
Journal of the American College of Radiology : JACR|February 17, 2026
ACR Appropriateness Criteria® Staging and Follow-up of Gastric Cancer, Priya R Bhosale, Mayur K Virarkar, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2018
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to ArmsRoberto A Salas Fragomeni, Tali Amir, Sara Sheikhbahaei, et al.
BJU International|September 23, 2024
The use of <sup>99m</sup>Tc-tetrofosmin in the characterisation of indeterminate renal masses: a pilot studyErgi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerAndrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2025
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [<sup>177</sup>Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate CancerLoïc Djaileb, Andrea Farolfi, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 11, 2025
[<sup>68</sup>Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based ChemotherapyStephan Beintner-Skawran, Andrei Gafita, Theo Lorenzini, et al.
Journal of the American College of Radiology : JACR|March 21, 2026
ACR Appropriateness Criteria® Penetrating Trauma-Abdomen and Pelvis: Update 2026, Daniel N Costa, Michael Bass, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
PSMA PET/CT-Derived Indicators and Outcomes After [<sup>177</sup>Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access ProgramKoichiro Kimura, Vishnu Murthy, Andrew F Voter, et al.
Journal of the American College of Radiology : JACR|February 17, 2026
ACR Appropriateness Criteria® Staging and Follow-up of Gastric Cancer, Priya R Bhosale, Mayur K Virarkar, et al.
Pageof 12